Fluicell AB (FRA:5J90) Total Liabilities: €0.61 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5J90 Fluicell AB FRA:5J90
61 GF Score
Price €2.93
GF Value €2.88
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Total Liabilities?

Fluicell AB FRA:5J90 -5.48% 61 Total Liabilities is €0.61 Mil as of Mar. 2026. GuruFocus rates FRA:5J90 with a GF Score™ of 61/100 and a GF Value™ of €2.88 (Fairly Valued). The stock has 4 warning signs investors should review.

Fluicell AB's Total Liabilities for the quarter that ended in Mar. 2026 was €0.61 Mil.

Fluicell AB's quarterly Total Liabilities increased from Sep. 2025 (€0.51 Mil) to Dec. 2025 (€0.70 Mil) but then declined from Dec. 2025 (€0.70 Mil) to Mar. 2026 (€0.61 Mil).

Fluicell AB's annual Total Liabilities declined from Dec. 2023 (€0.80 Mil) to Dec. 2024 (€0.55 Mil) but then increased from Dec. 2024 (€0.55 Mil) to Dec. 2025 (€0.70 Mil).

Fluicell AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Total Liabilities Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 0.76 0.80 0.55 0.70

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.47 0.51 0.70 0.61
FRA:5J90
61GF Score
Fluicell AB FRA:5J90
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fluicell AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.696+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.70

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.698-1.002
=0.70

Fluicell AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.609+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.61

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1.928-1.319
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.61 Mil mean?
Fluicell AB (FRA:5J90) has a Total Liabilities of €0.61 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fluicell AB and its competitors.
Is Fluicell AB's Total Liabilities too high?
Fluicell AB's current Total Liabilities is €0.61 Mil. Overall, Fluicell AB has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Total Liabilities compare to VRTX and REGN?
Fluicell AB's Total Liabilities of €0.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fluicell AB and its competitors. Fluicell AB's current Total Liabilities is €0.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Fairly Valued. The stock's GF Value™ is €2.88, compared to a current price of €2.93 — trading 1.7% above its estimated fair value. The current Total Liabilities is €0.61 Mil. Fluicell AB's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current Total Liabilities is €0.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (FRA:5J90) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued. The current stock price of €2.93 is trading 1.7% above its estimated GF Value™ of €2.88. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for FRA:5J90:

  • Total Liabilities: €0.61 Mil
  • GF Value™: €2.88 vs. price of €2.93 (1.7% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges FLUI:Sweden
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
61GF Score

Get the complete analysis for FRA:5J90

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.93
Price
€2.88
GF Value